Compare · ARDX vs ZSAN
ARDX vs ZSAN
Side-by-side comparison of Ardelyx Inc. (ARDX) and Zosano Pharma Corporation (ZSAN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARDX and ZSAN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ARDX is the larger of the two at $1.37B, about 27.5x ZSAN ($49.7M).
- ARDX has hit the wire 14 times in the past 4 weeks while ZSAN has been quiet.
- ARDX has more recent analyst coverage (23 ratings vs 1 for ZSAN).
- Company
- Ardelyx Inc.
- Zosano Pharma Corporation
- Price
- $5.54-0.45%
- $0.61+12.96%
- Market cap
- $1.37B
- $49.7M
- 1M return
- -20.56%
- -
- 1Y return
- +47.87%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- 2015
- News (4w)
- 14
- 0
- Recent ratings
- 23
- 1
Ardelyx Inc.
Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program that is in Phase 2 clinical trial for the treatment of patients with hyperkalemia; and RDX020, a small molecule program for the treatment of metabolic acidosis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Fremont, California.
Zosano Pharma Corporation
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.
Latest ARDX
- SEC Form DEFA14A filed by Ardelyx Inc.
- Officer Reilly Joseph James sold $23,309 worth of shares (3,719 units at $6.27), decreasing direct ownership by 1% to 149,836 units (SEC Form 4) (withholding tax)
- Chief Financial Officer Hohenleitner Susan sold $9,119 worth of shares (1,455 units at $6.27), decreasing direct ownership by 0.63% to 229,078 units (SEC Form 4) (for withholding tax)
- Officer Bishop John E sold $14,453 worth of shares (2,306 units at $6.27), decreasing direct ownership by 0.68% to 336,845 units (SEC Form 4) (tax liability)
- Chief Human Resources Officer Brady James Parker sold $11,570 worth of shares (1,846 units at $6.27), decreasing direct ownership by 0.70% to 261,066 units (SEC Form 4) to satisfy tax liability
- Chief Commercial Officer Foster Eric Duane sold $50,127 worth of shares (7,998 units at $6.27), decreasing direct ownership by 2% to 417,972 units (SEC Form 4) to satisfy withholding obligation
- Chief Business Officer Kelliher Mike sold $45,427 worth of shares (7,248 units at $6.27), decreasing direct ownership by 2% to 357,418 units (SEC Form 4) to cover withholding tax
- Chief Patient Officer Williams Laura A sold $43,804 worth of shares (6,989 units at $6.27), decreasing direct ownership by 2% to 429,093 units (SEC Form 4) (withholding obligation)
- President & CEO Raab Michael sold $343,133 worth of shares (54,748 units at $6.27), decreasing direct ownership by 3% to 1,720,033 units (SEC Form 4) (withholding obligation)
- SEC Form 144 filed by Ardelyx Inc.
Latest ZSAN
- SEC Form 25-NSE filed by Zosano Pharma Corporation
- 12 Health Care Stocks Moving In Friday's After-Market Session
- SEC Form 4: Matthews Christine sold $58 worth of shares (82 units at $0.71), decreasing direct ownership by 2% to 4,183 units to satisfy withholding obligation
- SEC Form 4: Lo Steven sold $314 worth of shares (442 units at $0.71), decreasing direct ownership by 3% to 13,163 units (withholding obligation)
- 16 Stocks Moving in Tuesday's Pre-Market Session
- 95 Biggest Movers From Yesterday
- 12 Health Care Stocks Moving In Monday's After-Market Session
- 52 Stocks Moving In Monday's Mid-Day Session
- 69 Biggest Movers From Yesterday
- 12 Health Care Stocks Moving In Friday's Intraday Session